-
Mashup Score: 0Copanlisib Shows Clinical Activity in PIK3CA-Mutated Tumors - 2 year(s) ago
Patients with tumors harboring PIK3CA mutations reported a better objective response rate when given copanlisib compared to those with the null hypothesis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 2 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 2 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 2 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 2 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 1Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 2 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib-Rituximab Combo Improves Survival for Indolent NHL - 3 year(s) ago
Combining copanlisib with rituximab significantly extends progression-free survival in patients with indolent non-Hodgkin lymphoma, with an acceptable safety profile, according to results of the phase 3 CHRONOS-3 trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combining #copanlisib with #rituximab significantly extends PFS in indolent NHL. https://t.co/vBBJOfCdvL @DrMatasar @sloan_kettering @AACR #AACR21 #NHL #lymphoma
-
-
Mashup Score: 0Copanlisib-Rituximab Combo Improves Survival for Indolent NHL - 3 year(s) ago
Combining copanlisib with rituximab significantly extends progression-free survival in patients with indolent non-Hodgkin lymphoma, with an acceptable safety profile, according to results of the phase 3 CHRONOS-3 trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combining #copanlisib with #rituximab significantly extends PFS in patients with indolent NHL. https://t.co/AKNsEp22y6 @DrMatasar @sloan_kettering @AACR #AACR21 #NHL #lymphoma
-
-
Mashup Score: 5
Copanlisib plus rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab. To our knowledge, copanlisib is the first PI3K inhibitor to be safely combined with rituximab and the first to show broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Presented at #AACR21 and now in the May issue: CHRONOS-3 - #Copanlisib plus #rituximab vs placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma: a randomised, controlled, phase 3 trial #NonHodgkinLymphoma #lymsm https://t.co/wfjUQ7F27R
-
-
Mashup Score: 0Lymphoma Daily - 3 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/SYlz4N0pM6 Thanks to @CancerNetwrk @MarkQuarter @AtriumHealth #nonhodgkinslymphoma #copanlisib
-
Patients with tumors harboring #PIK3CA mutations reported a better objective response rate when given #copanlisib compared to those with the null hypothesis. #oncology https://t.co/rpLn83qFa8